Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review.

Schmidt PHS, Pasqualotto E, Dos Santos HV, de Souza LSN, Dos Santos BE, Chavez MP, Ferreira ROM, Hohl A, Ronsoni MF, van de Sande-Lee S

Obesity research & clinical practice1 Jan 2025Cited by 13 (Europe PMC)

PMID39904668DOI10.1016/j.orcp.2025.01.009PepBankPUB-39904668

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanSystematic reviewEfficacy outcome
Across included trials in people with overweight or obesity, liraglutide reduced total weight versus placebo.
In plain wordsIn reviewed people with overweight/obesity, liraglutide reduced total weight more than placebo.
Peptide
Liraglutide
Outcome
DecreaseTotal weight
Study
n = 960
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide consistently demonstrated significant reductions in total weight, fat mass, and visceral adipose tissue (VAT) compared to placebo across the included studies.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effect of liraglutide on body composition in people living with obesity or overweight.MethodsA systematic search was conducted in PubMed, Embase, and Cochrane Library databases up to June 10, 2024. Randomized controlled trials (RCTs) comparing liraglutide to placebo and repo…
Summary · context
Data from 15 studies involving 960 participants were analyzed.
Report a problemFND-3990466801
02HumanSystematic reviewEfficacy outcome
Across included trials in people with overweight or obesity, liraglutide reduced fat mass versus placebo.
In plain wordsIn reviewed people with overweight/obesity, liraglutide reduced fat mass more than placebo.
Peptide
Liraglutide
Outcome
DecreaseFat mass
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
Liraglutide consistently demonstrated significant reductions in total weight, fat mass, and visceral adipose tissue (VAT) compared to placebo across the included studies.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effect of liraglutide on body composition in people living with obesity or overweight.MethodsA systematic search was conducted in PubMed, Embase, and Cochrane Library databases up to June 10, 2024. Randomized controlled trials (RCTs) comparing liraglutide to placebo and repo…
Summary · context
Data from 15 studies involving 960 participants were analyzed.
Report a problemFND-3990466802
03HumanSystematic reviewEfficacy outcome
Across included trials in people with overweight or obesity, liraglutide reduced visceral adipose tissue by 12.49% to 23% versus placebo.
In plain wordsIn reviewed people with overweight/obesity, liraglutide reduced visceral fat more than placebo.
Peptide
Liraglutide
Outcome
DecreaseVisceral adipose tissue
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated
Measurements
VAT reduction
12.49 to 23%
liraglutide
Source sentences
Summary
Liraglutide consistently demonstrated significant reductions in total weight, fat mass, and visceral adipose tissue (VAT) compared to placebo across the included studies.
3 context sentences(design, population, supporting numbers)
Summary · context
VAT reductions ranged from 12.49 % to 23 %, highlighting liraglutide's effectiveness in targeting visceral fat, a key factor in cardiometabolic risk.
Summary · context
To evaluate the effect of liraglutide on body composition in people living with obesity or overweight.MethodsA systematic search was conducted in PubMed, Embase, and Cochrane Library databases up to June 10, 2024. Randomized controlled trials (RCTs) comparing liraglutide to placebo and repo…
Summary · context
Data from 15 studies involving 960 participants were analyzed.
Report a problemFND-3990466803
04HumanSystematic reviewEfficacy outcome
Across included trials, liraglutide's lean mass outcomes varied, with preservation or gains in some studies and losses in others.
In plain wordsIn reviewed people with overweight/obesity, liraglutide lean-mass findings varied from preservation or gains to losses; the exact reference was unstated.
Peptide
Liraglutide
Outcome
MixedLean mass
Study
n: not reported in source
Outcome group
Body composition · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
In contrast, lean mass outcomes were more variable, with some studies reporting preservation or even gains in lean mass, while others indicated losses.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate the effect of liraglutide on body composition in people living with obesity or overweight.MethodsA systematic search was conducted in PubMed, Embase, and Cochrane Library databases up to June 10, 2024. Randomized controlled trials (RCTs) comparing liraglutide to placebo and repo…
Summary · context
Data from 15 studies involving 960 participants were analyzed.
Report a problemFND-3990466804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.